Jones B M, White A D, Culligan D J, Jacobs A
Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, UK.
Cancer Genet Cytogenet. 1992 Aug;62(1):66-9. doi: 10.1016/0165-4608(92)90041-6.
The proliferation characteristics of leukemic cells may be a determining factor in disease course and response to therapy. The present study compares the rate of cell-cycle progression in the bone marrow of 16 hematologically normal subjects, 19 patients with acute myeloid leukemia (AML), and 23 patients with myelodysplastic syndrome (MDS). The frequency of sister chromatid exchanges (SCE) in bone marrow cells is also compared. MDS and AML patients showed a reduction in the rate of cell-cycle progression compared with normal subjects. Patients with 'high risk' MDS (RAEB/RAEB-t) did not differ significantly from patients with AML but had a significantly slower rate of cell-cycle progression than patients with 'low-risk' MDS (PASA/RA). There was no correlation between the rate of cell-cycle progression and clonal karyotype status or the percentage of blast cells in either MDS or AML. There were no significant differences in SCE frequency between normal subjects and MDS or AML patients.
白血病细胞的增殖特性可能是疾病进程和对治疗反应的一个决定性因素。本研究比较了16名血液学正常受试者、19名急性髓系白血病(AML)患者和23名骨髓增生异常综合征(MDS)患者骨髓中细胞周期进程的速率。还比较了骨髓细胞中姐妹染色单体交换(SCE)的频率。与正常受试者相比,MDS和AML患者的细胞周期进程速率降低。“高危”MDS(RAEB/RAEB-t)患者与AML患者相比无显著差异,但细胞周期进程速率明显慢于“低危”MDS(PASA/RA)患者。在MDS或AML中,细胞周期进程速率与克隆核型状态或原始细胞百分比之间均无相关性。正常受试者与MDS或AML患者之间的SCE频率无显著差异。